Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health Canada clears Vivimind

This article was originally published in The Tan Sheet

Executive Summary

Ovos Natural Health receives a Natural Health Product Number for its homotaurine amino acid supplement, allowing the Laval, Quebec, firm to sell Vivimind at retail in Canada. The issuance from Health Canada, announced Sept. 30, allows Ovos "to move forward with our search for a partner to commercialize Vivimind on a larger scale in Canada," where it previously was available only online, said Roberto Bellini, CEO of parent company Bellus Health. Ovos said it hoped to introduce the cognitive health product in the U.S. in 2010, but still has not received a reply from FDA on its citizen petition asking for permission to market homotaurine, a former investigational new drug candidate, as a new dietary ingredient (1"The Tan Sheet" Aug. 2, 2010)

You may also be interested in...



FDA Clear On Supplement Ingredient Petitions, But Still Fuzzy On Sec. 912

FDA says current dietary supplement regulations make clear that citizen petitions can be filed to request approval of ingredients that were studied in clinical trials and were part of unsuccessful investigational new drug applications

Stock Watch: Digging Holes And Clutching At Straws In Biotech R&D

Biotech CEOs often express surprise when the FDA rejects their drugs. But collaborative interactions between regulators and drug sponsors count for little if the latter fail to adjust their clinical and regulatory efforts accordingly.

Chinese-Language Podcast: ESMO上的中国数据

Special guest, Citeline's Annie Siu, discusses the recent ESMO meeting and Jiangsu Hengrui and BeiGene's PD-1 data for hepatocellular carcinoma in this latest episode of the Chinese-language China Biotech podcast.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS104585

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel